- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02005107
Venlafaxine PK Following Bariatric Surgery (VLX)
April 4, 2016 updated by: Kristine Steffen, North Dakota State University
A Comparison of Immediate and Extended Release Venlafaxine Following Bariatric Surgery
This study is being conducted to evaluate how the body absorbs and processes the immediate release (IR) and sustained release (XR) medication venlafaxine (Effexor®).
Subject who are 1-3 years post gastric bypass or sleeve gastrectomy surgery will be invited to participate.
Non-surgical controls will also be enrolled based on a matching criteria to post gastric bypass subjects.
Participants will be asked to complete two 12-hour study days approximately 11 days apart.
This study will enroll up to 30 participants.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Dakota
-
Fargo, North Dakota, United States, 58103
- Neuropsychiatric Research Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or Female
- Age 18-65 (inclusive, at time of informed consent)
- No tobacco use in the past three months.
- Underwent Roux-en-Y Gastric Bypass or Sleeve Gastrectomy weight loss surgery 12-36 months prior to study OR has not had a weight loss surgery but matches the gastric bypass patients on age, gender, and BMI. Criteria for matching will be established at the beginning of the study in consultation with the statistical team and addressed as needed with the input of the biostatistician.
- Ability to read, write and understand English
Exclusion Criteria:
- Taking a medication that has a clinically significant interaction with venlafaxine or an interaction that may alter the study data.
- Hypersensitivity to venlafaxine or any excipient contained within the dosage forms
- Inability to tolerate repeated blood draws.
- Any history of bipoloar disorder or a psychotic disorder.
- Current major depressive disorder or current suicidality.
- Alcohol or substance dependence in the past year.
- Currently pregnant or lactating or unwillingness to use medically accepted contraception during study
- Taking a medication which significantly alters gastrointesinal transit time or significantly reduces acid secretion (e.g. routine use of proton pump inhibitors, H2 antagonists, sucralfate).
- Medical conditon which may increase participant risk with venlafaxine or uncontrolled hypertension at the discretion of the examining provider.
- Hepatic insufficiency as defined by any hepatic enzyme greater than 3x the upper limit of normal or other hepatic laboratory abnormalities at the discretion of the medical provider.
- Renal impairment as evidence by a calculated creatinine clearance of less than or equal to 70ml/min or other abnormality on a renal panel that the medical provider feels puts the participant at risk.
- Poor or ultra-rapid Cytochrome P450 2D6 metabolizer.
- Self reported history of viral hepatits or HIV.
- Positive urine drug screen unless documented prescription of a non-interacting medication.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: venlafaxine
Venlafaxine IR and XR, single dosages of each separated by a wash-out period
|
Other Names:
|
Other: Venlafaxine XR and Venlafaxine IR
Each participant (3 groups of participants) will receive one dose of venlafaxine IR and one dose of venlafaxine XR seperated by a wash-out period.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Venlafaxine Plasma Concentrations/Area-Under-the-Curve (AUC)
Time Frame: 24 hours intervals
|
The primary aim of this research is to provide a comparison of pharmacokinetic measures associated with a single dose of venlafaxine IR (immediate release) and venlafaxine XR (sustained release) in Roux-en-Y Gastric Bypass, Sleeve Gastrectomy, and matched nonsurgical "control" subjects.
Comparisons will be based upon venlafaxine plasma concentrations obtained during the 24 hour sample collection window.
|
24 hours intervals
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Secondary PK Characteristics (Composite)
Time Frame: 24 hour collection
|
We will also evaluate other PK characteristics associated with venlafaxine, such as Cmax, Tmax, t1/2, and the ratio of venlafaxine to the active metabolite ODV, and others.
|
24 hour collection
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Kristine J Steffen, Pharm.D., Ph.D., North Dakota State University & Neuropsychiatric Research Institute
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2013
Primary Completion (Actual)
March 1, 2015
Study Completion (Actual)
March 1, 2015
Study Registration Dates
First Submitted
December 3, 2013
First Submitted That Met QC Criteria
December 3, 2013
First Posted (Estimate)
December 9, 2013
Study Record Updates
Last Update Posted (Estimate)
April 6, 2016
Last Update Submitted That Met QC Criteria
April 4, 2016
Last Verified
April 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Antidepressive Agents
- Antidepressive Agents, Second-Generation
- Serotonin and Noradrenaline Reuptake Inhibitors
- Venlafaxine Hydrochloride
Other Study ID Numbers
- KSteffenVLX
- EPSCOR (Other Identifier: North Dakota State University)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sleeve Gastrectomy
-
Methodist Health SystemIntuitive SurgicalRecruitingLaparoscopic Sleeve Gastrectomy | Sleeve GastrectomyUnited States
-
Miguel BurchCedars-Sinai Medical CenterTerminated
-
University of MiamiEnrolling by invitation
-
Universiti Putra MalaysiaUnknownLaparoscopic Sleeve Gastrectomy
-
Beijing Friendship HospitalPeking Union Medical College Hospital; Beijing Tiantan Hospital; Beijing Hospital and other collaboratorsCompleted
-
Fatih Sultan Mehmet Training and Research HospitalCompletedLaparoscopic Sleeve Gastrectomy
-
Tanta UniversityNot yet recruitingOptic Nerve Sheath Diameter | Laparoscopic Sleeve Gastrectomy
-
University of Illinois at Urbana-ChampaignCarle Foundation HospitalRecruiting
-
Icahn School of Medicine at Mount SinaiCompletedLaparoscopic Sleeve Gastrectomy | Subcostal Transversus Abdominis Plane BlockUnited States
-
King Saud UniversityKing Saud Medical CityCompletedObesity | Laparoscopic Sleeve Gastrectomy | Endoscopic Sleeve GastroplastySaudi Arabia
Clinical Trials on Venlafaxine IR and Venlafaxine XR
-
ShireCompletedHealthyUnited States
-
University of WashingtonUniversity of Miami; University of Alabama at Birmingham; New York University; University... and other collaboratorsCompletedMajor Depressive Disorder | Spinal Cord Injuries | DysthymiaUnited States
-
Xijing HospitalUnknown
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedDepression | Anxiety Disorders
-
University of PittsburghCompletedDepressionUnited States
-
Janssen Research & Development, LLCTerminated
-
Dr. Reddy's Laboratories LimitedCompleted
-
University of MichiganU.S. Department of EducationCompletedSpinal Cord InjuryUnited States
-
Guangzhou General Hospital of Guangzhou Military...CompletedIschemic Stroke | Subcortical AphasiaChina
-
Actavis Inc.Completed